𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Molecular Monitoring of BCR-ABL Transcripts in Patients With Chronic Myelogenous Leukemia: Is High Sensitivity of Clinical Value?

✍ Scribed by Maxim Norkin; Charles A. Schiffer

Book ID
107540269
Publisher
Current Science Inc.
Year
2010
Tongue
English
Weight
143 KB
Volume
5
Category
Article
ISSN
1558-8211

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Applicability of an absolute quantitativ
Applicability of an absolute quantitative procedure to monitor intra-individual bcr/abl transcript kinetics in clinical samples from chronic myelogenous leukemia patients
✍ Karl-Anton Kreuzer; Ulrich Lass; Stefan Nagel; Heinz Ellerbrok; Georg Pauli; BΓ€r πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 French βš– 149 KB

Chimeric bcr/abl fusion proteins are thought to be the molecular 'pathogen' of chronic myelogenous leukaemia (CML). Expression levels of the respective fusion RNAs reflect disease progression as well as remission upon therapeutic intervention in CML patients. However, there is no quick and reliable

Molecular diagnosis and monitoring in th
Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors
✍ Joyce Ou; Jo-Anne Vergilio; Adam Bagg πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 161 KB πŸ‘ 2 views

## Abstract The well‐established molecular pathogenesis of chronic myelogenous leukemia (CML) and its consequences for laboratory testing and clinical management illustrate a classic paradigm for the importance of molecular diagnostics in targeted drug therapy. The success of the tyrosine kinase in

Absence of the hybrid bcr-abl mRNA in Ph
Absence of the hybrid bcr-abl mRNA in Ph1-positive B lymphoblastoid cell lines established from a patient with chronic myelogenous leukemia
✍ Toshiyuki Yamada; Tsuneyuki Oikawa; Noboru Kuzumaki; Nobuo Takagi; Motomichi Sas πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 French βš– 1015 KB

The expression of c-abl, c-sis, c-myc and N-ras oncogenes was examined in 2 lymphoblastoid cell lines, one with Ph1 (PB-1049) and the other without Ph1 (LN-1049), both established from a patient with chronic myelogenous leukemia (CML), and in a Ph1-positive cell line (PB-1049-T) derived from a tumor